Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Perspective Therapeutics, Inc.CATX · Entity 694 | Director | March 02, 2026 | March 04, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Perspective Therapeutics, Inc.
Report date March 02, 2026 · Filed March 04, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.35 · Expires 2036-03-02 | Direct | 50,000 |
Reported balance
After 2026-03-02 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-03-02 · Grant · Acquired 50,000 · Balance 50,000 F1: The option grant was approved by the Issuer's Board of Directors on January 26, 2026, with a grant date of March 2, 2026, and represents the Reporting Person's annual equity award for 2026. F2: Option vests in full on March 2, 2027, subject to the Reporting Person's continued service on the vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option grant was approved by the Issuer's Board of Directors on January 26, 2026, with a grant date of March 2, 2026, and represents the Reporting Person's annual equity award for 2026.
F2: Option vests in full on March 2, 2027, subject to the Reporting Person's continued service on the vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 13, 2018 Filed Jun 20, 2018 00:27 UTC | Perspective Therapeutics, Inc. ISR · Entity 694 | GrantStock Options (right to buy) · Derivative | 250,000 | $0.00 Strike: $0.46 | $0.00 |
DisclosureSEC source: 0001437749-18-012097 · rdgdoc.xml · derivative · entry 1 Woods Lori A · CIK 0001393007 · Director · Interim CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 350,000 Underlying: Common Stock · 250,000 shares Expires 2028-06-13 F1 · derivative.exercise_date: 25% vests as of 12/13/2018, and the remaining 75% will vest over the next three (3) years, commencing on 6/13/2019, until fully vested. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.